Cannabidiol and Canabis Use Disorder María S. García-Gutiérrez, Francisco Navarrete, Adrián Viudez-Martínez, Ani Gasparyan, Esther Caparrós, Jorge Manzanares Chapter, In book : "Cannabis Use Disorders", 2018, pp 31-42 DOI: 10.1007/978-3-319-90365-1_5 Abstract Cannabis use disorders (CUD) represent a serious public health problem in occidental societies. Despite their devastating social, health, and economic impact, to date no pharmacological treatment has been approved for the clinical management of cannabis dependence. Cannabidiol (CBD), one of the main compounds—together with Δ9-THC—present in the plant Cannabis sativa, has been reported to possess anxiolytic, antidepressant, and antipsychotic-like effects and neuroprotective properties. And, contrary to Δ9-THC, CBD does not appear to have addictive properties. Taken [...]
Lire la suiteDetoxification from methadone using low, repeated, and increasing doses of ibogaine : A case report CLARE WILKINS, RAFAEL G. DOS SANTOS, JORDI SOLÁ, MARC AIXALÁ, PEP CURA, ESTEFANÍA MORENO, MIGUEL ÁNGEL ALCÁZAR-CÓRCOLES, JAIME E. C. HALLAK and JOSÉ CARLOS BOUSO Journal of Psychedelic Studies, 2017, 1, (1), pp. 29–34 DOI: 10.1556/2054.01.2017.005 Background and aims : Ibogaine is a natural alkaloid that has been used in the last decades as an adjuvant for the treatment of opiate withdrawal. Despite the beneficial results suggested by animal studies and case series, there is a lack of clinical trials to assess the safety and efficacy of ibogaine. Moreover, [...]
Lire la suiteSubjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning ALAN K. DAVIS, JOSEPH P. BARSUGLIA, MARLEY WINDHAM-HERMAN, MARTA LYNCH and MARTIN POLANCO Journal of Psychedelic Studies, 2017, 1, (2), pp. 65–73 DOI: 10.1556/2054.01.2017.009 Background and aims : Very few studies have reported the effectiveness of ibogaine as a treatment for chronic opioid use. Therefore, this study evaluated the acute subjective effects of ibogaine, outcomes on problematic opioid consumption, and the long-term associations with psychological functioning. Methods : Using online data collection, 88 patients who received ibogaine treatment in Mexico between 2012 and 2015 completed our survey. Results : [...]
Lire la suiteAntidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report Flavia de L. Osorio, Rafael F. Sanches, Ligia R. Macedo, Rafael G. dos Santos, Joao P. Maia-de-Oliveira, Lauro Wichert-Ana, Draulio B. de Araujo, Jordi Riba, Jose´ A. Crippa, Jaime E. Hallak Revista Brasileira de Psiquiatria, 2015, 37, 13–20 doi:10.1590/1516-4446-2014-1496 Objectives : Ayahuasca (AYA), a natural psychedelic brew prepared from Amazonian plants and rich in dimethyltryptamine (DMT) and harmine, causes effects of subjective well-being and may therefore have antidepressant actions. This study sought to evaluate the effects of a single dose of AYA in six volunteers with a current depressive episode. Methods : [...]
Lire la suiteMedical Cannabis : Effects on Opioid and Benzodiazepine Requirements for Pain Control. Megan O’Connell, PharmD, Megan Sandgren, PharmD, MS, BCPS, Leah Frantzen, PharmD, BCPS, Erika Bower, PharmD, BCACP, Brian Erickson, MD Annals of Pharmacotherapy, 2019 May 25:1060028019854221. doi: 10.1177/1060028019854221. PMID : 31129977 Abstract BACKGROUND : There is currently little evidence regarding the use of medical cannabis for the treatment of intractable pain. Literature published on the subject to date has yielded mixed results concerning the efficacy of medical cannabis and has been limited by study design and regulatory issues. OBJECTIVE: The objective of this study was to determine if the use of medical [...]
Lire la suiteAwareness of Emotional Expressions in Cannabis Users : An Event-Related Potential Study Robert D. Torrence, Donald C. Rojas and Lucy J. Troup Frontiers in Psychology, February 2019 | Volume 10 | Article 69 ORIGINAL RESEARCH doi: 10.3389/fpsyg.2019.00069 Abstract Cannabis use has been associated with anxiogenic effects when used in low frequency for a short duration, but cannabis can also have anxiogenic effects when used heavily for a long duration. Animal studies have indicated the neurobiological mechanisms related to cannabis and anxiety; however, research has been limited on the related neurocognitive mechanisms. Previous research has indicated that cannabis use is associated with alterations in event-related potentials (ERPs). [...]
Lire la suiteMarijuana Compounds : A Non-Conventional Therapeutic Approach to Epilepsy in Children Mariana Babayeva, Malka Fuzailov, Paulina Rozenfeld and Paramita Basu Journal of Addiction and Neuropharmacology, 2014, 1, 1, 002 Abstract Epilepsy in children is a complex disease, with a variety of distinct syndromes and many alternative treatment options. Even with a plethora of available treatment options, childhood epilepsies are commonly associated with seizures that are resistant to existing treatment methods. Treatment of pediatric epilepsy is challenging and requires more effective therapy to avoid short-term and longterm neurological disorders. Marijuana has been used to treat disease since ancient times. Marijuana ingredients Cannabidiol (CBD) and D9- Tetrahydrocannabinol (THC) [...]
Lire la suiteLes cannabinoïdes dans l’Autisme : Dr Christian Sueur GRECC (Groupe de Recherches et D’Etudes Cliniques sur les Cannabinoïdes) Version actualisée juin 2019 L’autisme est une pathologie, ou plutôt un trouble majeur du développement psycho-neuro-développemental, à l’étiologie complexe et multifactorielle ; rentrent vraisemblablement en interaction, pour produire un trouble du spectre autistique, aussi bien des facteurs psychologique interactionnels précoces, qu’un terrain de fragilité ou de prédisposition génétique, à l’origine d’anomalies neurophysiologiques du développement de la connectique neuronale. Depuis près d’une vingtaine d’année, les cannabinoïdes représente progressivement une nouvelle voie d’approche thérapeutique des autismes les plus sévères. Certains parents, surtout aux USA[1], ont adopté depuis le début [...]
Lire la suiteCannabis Use in Pregnancy. A Tale of 2 Concerns Michael Silverstein, MD, MPH1,2; Elizabeth A. Howell, MD, MPH3; Barry Zuckerman, MD1 JAMA. Published online June 18, 2019. doi:10.1001/jama.2019.8860 Original Investigation Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes Daniel J. Corsi, PhD; Laura Walsh, MSc; Deborah Weiss, PhD; Helen Hsu, MD; Darine El-Chaar, MD; Steven Hawken, PhD; Deshayne B. Fell, PhD; Mark Walker, MD Research Letter Medical and Nonmedical Cannabis Use Among Pregnant Women in the United States Nora D. Volkow, MD; Beth Han, MD, PhD, MPH; Wilson M. Compton, MD, MPE; Elinore F. McCance-Katz, MD, PhD Full Text, https://jamanetwork.com/journals/jama/article-abstract/2736581 In an article in JAMA, Corsi and colleagues1 present the results of a retrospective cohort study of 661 617 women designed to assess associations between maternal cannabis use during pregnancy and adverse obstetrical and [...]
Lire la suiteAssociation Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes Daniel J. Corsi, PhD; LauraWalsh, MSc; DeborahWeiss, PhD; Helen Hsu, MD; Darine El-Chaar, MD; Steven Hawken, PhD; Deshayne B. Fell, PhD; MarkWalker,MD JAMA, Published online June 18, 2019. doi:10.1001/jama.2019.8734 Key Points Question Is there an association between prenatal cannabis exposure and maternal, perinatal, and neonatal outcomes? Findings In this retrospective cohort study that included 661 617 pregnancies and 9427 reported cannabis users, the rate of preterm birth among reported cannabis users was 12% vs 6% in nonusers, a statistically significant difference. Meaning Reported cannabis use in pregnancy was associated with significant increases in the rate of preterm [...]
Lire la suite